GL Ventures

Activity from announced rounds

All recorded activity

GL Ventures is the Hillhouse-origin early-stage venture firm identified in LTZ and Clipto issuer announcements.

Recorded funding activity

LTZ develops cancer immunotherapies targeting myeloid biology. Clipto supplies tools for searching video and audio libraries, while Anew combines AI models and experiments for drug discovery. These histories remain distinct from the Hillhouse parent and named funds.

Sources
Rounds participated in
14
Confirmed lead rounds
2
4 roles undisclosed
New companies
13
First participation on record · 1 follow-on
Funding in participating rounds
$623M
6 disclosed · full round size, not this investor’s share

By stage

Undisclosed7
Seed5
Series B2

By primary sector

AI6
Biotech3
Robotics3
Hardware1
Healthtech1

By country

China10
United States3
Singapore1

Rounds

14 in all activity
CleerScience

CleerScience applies AI to materials research, characterization and industrial development.

Participant
Esonitro

Esonitro develops flexible neural electrodes and brain-computer interface technology, including its movable NeuroWorm electrode.

~CN¥100MAngel+
Participant
Anew Labs

An AI drug-discovery company that combines molecular models, experimental biology and a drug pipeline to identify and develop new medicines.

$290MFunding
Lead
Clipto

Clipto builds AI tools for searching and working with video and audio libraries.

$15MFunding
Participant
LatentVerse

LatentVerse develops foundation models that combine perception, prediction and robot action.

Participant
MoSense

MoSense builds flexible tactile skin and sensing systems for robots.

Participant
Litchibot

Litchibot develops physical-AI infrastructure that lets robot skills transfer across hardware.

Participant
Approaching.AI

Approaching.AI develops inference services and infrastructure that help enterprises run large language models efficiently.

UndisclosedPre-Series A
Participant
LTZ Therapeutics

LTZ Therapeutics develops cancer immunotherapies that target myeloid biology.

$38MUndisclosed
Role not disclosed
Syneron Bio

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B
Role not disclosed
Dify

Helps teams build deploy and operate production-grade AI applications and agentic workflows

$30MPre-Series A
Role not disclosed
EPG

Provides modular and prefabricated data center infrastructure

$100MSeries B
Role not disclosed
Approaching.AI

Approaching.AI develops inference services and infrastructure that help enterprises run large language models efficiently.

UndisclosedAngel round
Lead